 |
 Play Video: The Importance of Insider Buying
|
|
|
| Date | Insider | Price | Amount |
|---|
3-11-2020
Insider Buy |
Roy Winston
Chief Clinical Officer |
$36.50
CAGR »
|
$91,250.00
2,500 shares |
3-6-2019
Insider Buy |
Mark A. Kronenfeld
Director |
$38.97
CAGR »
|
$66,244.00
1,700 shares |
11-19-2018
Insider Buy |
Gary W. Pace
Director |
$46.18
CAGR »
|
$207,810.00
4,500 shares |
11-7-2018
Insider Buy |
Gary W. Pace
Director |
$51.29
CAGR »
|
$205,160.00
4,000 shares |
8-28-2018
Insider Buy |
Mark A. Kronenfeld
Director |
$44.61
CAGR »
|
$44,611.20
1,000 shares |
11-10-2017
Insider Buy |
Mark A. Kronenfeld
Director |
$41.60
CAGR »
|
$41,602.50
1,000 shares |
8-8-2017
Insider Buy |
Mark Froimson
Director |
$37.13
CAGR »
|
$3,713.16
100 shares |
1-29-2016
Insider Buy |
Scott Braunstein
SVP, Strategy & Corp. Dev. |
$58.92
CAGR »
|
$117,840.00
2,000 shares |
1-27-2016
Insider Buy |
James B. Jones
SVP & Chief Medical Officer |
$62.50
CAGR »
|
$31,250.00
500 shares |
1-12-2016
Insider Buy |
James B. Jones
SVP & Chief Medical Officer |
$66.00
CAGR »
|
$66,000.00
1,000 shares |
1-12-2016
Insider Buy |
John P. Phd Longenecker
Director |
$66.55
CAGR »
|
$19,964.70
300 shares |
9-11-2015
Insider Buy |
James S. Scibetta
SVP, Chief Financial Officer |
$61.37
CAGR »
|
$306,850.00
5,000 shares |
3-13-2015
Insider Buy |
Gary W. Pace
Director |
$93.83
CAGR »
|
$93,829.90
1,000 shares |
12-5-2014
Insider Buy |
Dennis L. Winger
Director |
$94.54
CAGR »
|
$250,058.30
2,645 shares |
11-7-2014
Insider Buy |
Taunia Markvicka
SVP, Chief Commercial Officer |
$86.62
CAGR »
|
$19,922.60
230 shares |
11-3-2014
Insider Buy |
Mark A. Kronenfeld
Director |
$90.48
CAGR »
|
$76,908.00
850 shares |
9-11-2013
Insider Buy |
Mark A. Kronenfeld
Director |
$37.01
CAGR »
|
$37,010.00
1,000 shares |
5-15-2013
Insider Buy |
Paul J. Hastings
Director |
$29.30
CAGR »
|
$24,992.90
853 shares |
4-17-2012
Insider Buy |
Gary W. Pace
Director |
$9.75
CAGR »
|
$97,500.00
10,000 shares |
11-21-2011
Insider Buy |
Gary W. Pace
Director |
$6.50
CAGR »
|
$49,998.00
7,692 shares |
11-21-2011
Insider Buy |
Fred A. Middleton
Director and >10% Owner |
$6.50
CAGR »
|
$65,000.00
10,000 shares |
11-21-2011
Insider Buy |
Andreas Wicki
Director |
$6.50
CAGR »
|
$1,999,998.00
307,692 shares |
11-21-2011
Insider Buy |
Bioventures Cayman Ltd Hbm
>10% Owner |
$6.50
CAGR »
|
$1,999,998.00
307,692 shares |
11-21-2011
Insider Buy |
Luke Evnin
Director and >10% Owner |
$6.50
CAGR »
|
$2,999,997.00
461,538 shares |
11-21-2011
Insider Buy |
Vaughn M. Kailian
>10% Owner |
$6.50
CAGR »
|
$2,999,997.00
461,538 shares |
11-21-2011
Insider Buy |
Bioventures QP LP Mpm IV
>10% Owner |
$6.50
CAGR »
|
$2,999,997.00
461,538 shares |
2-8-2011
Insider Buy |
Bioventures QP LP Mpm IV
>10% Owner |
$7.00
CAGR »
|
$3,749,998.00
535,714 shares |
2-8-2011
Insider Buy |
Luke Evnin
Director and >10% Owner |
$7.00
CAGR »
|
$3,749,998.00
535,714 shares |
2-8-2011
Insider Buy |
Vaughn M. Kailian
>10% Owner |
$7.00
CAGR »
|
$3,749,998.00
535,714 shares |
2-15-2011
Insider Buy |
James S. Scibetta
Chief Financial Officer |
$7.04
CAGR »
|
$35,200.00
5,000 shares |
2-10-2011
Insider Buy |
David M. Stack
President and CEO |
$6.60
CAGR »
|
$33,000.00
5,000 shares |
2-8-2011
Insider Buy |
Andreas Wicki
Director |
$7.00
CAGR »
|
$3,749,998.00
535,714 shares |
2-8-2011
Insider Buy |
Bioventures Cayman Ltd Hbm
>10% Owner |
$7.00
CAGR »
|
$3,749,998.00
535,714 shares |
2-8-2011
Insider Buy |
Fred A. Middleton
Director |
$7.00
CAGR »
|
$1,874,999.00
267,857 shares |
2-8-2011
Insider Buy |
Carl L. Gordon
Director |
$7.00
CAGR »
|
$3,749,998.00
535,714 shares |
2-8-2011
Insider Buy |
ORBIMED ADVISORS LLC
>10% Owner |
$7.00
CAGR »
|
$3,749,998.00
535,714 shares |
Also See: Institutional Holders of PCRX
Also See: SEC filings
Below we present the annualized performance delivered by PCRX stock since 3-11-2020 (the date of the most recent
insider purchase). The performance of the investment from the time PCRX insider buying occurred is the ultimate
test of whether insiders were right about PCRX being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
03/12/2020 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$33.11 |
|
| End price/share: |
$26.33 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-20.48% |
|
| Average Annual Total Return: |
-5.40% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$7,952.91 |
|
| Years: |
4.13 |
|
PCRX Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent PCRX insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding PCRX
|
|
Free PCRX Email Alerts:
